AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12204667 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue tamoxifen treatment
Number of subjects: 306
Study 12204667 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop tamoxifen treatment
Number of subjects: 306
Study 12204667 — intervention group
Group type: COMPARATOR
Intervention: Declined randomisation - Stop tamoxifen
Number of subjects: 306
Study 12204667 — intervention group
Group type: COMPARATOR
Intervention: Declined randomisation - Continue tamoxifen
Number of subjects: 306
Study 12204667 — intervention group
Group type: COMPARATOR
Intervention: Declined randomisation - Unclear decision
Number of subjects: 306
Study 10527998 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF concentrations in SGA group (16.9 ± 6.6 ng/ml)
Number of subjects: 104
Study 10527998 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF concentrations in AGA group (16.7 ± 9.0 ng/ml)
Number of subjects: 104
Study 10527998 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF concentrations in LGA group (20.2 ± 14.8 ng/ml)
Number of subjects: 104
Study 10527998 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age in AGA group (34.2 ± 5.5 years)
Number of subjects: 104
Study 10527998 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth age, birth weight, neonatal height, and placental weight
Number of subjects: 104
Study 10527998 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I concentrations
Number of subjects: 104
Study 7667814 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) concentrates
Number of subjects: 0
Study 2143637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 38
Study 2143637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7424807 — intervention group
Group type: COMPARATOR
Intervention: High protein diet (45 g protein)
Number of subjects: 0
Study 7424807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur amino acid supplement (15 g protein plus sulfur amino acids)
Number of subjects: 0
Study 7424807 — intervention group
Group type: COMPARATOR
Intervention: Control diet (15 g protein)
Number of subjects: 0
Study 31274775 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 µg/kg/min)
Number of subjects: 72
Study 31274775 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (0.4 µg/kg/min)
Number of subjects: 72
Study 31274775 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 72
Study 31274775 — intervention group
Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 72
Study 28898204 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) plus Aspirin (40 μg, tid and 100 mg, qd)
Number of subjects: 308
Study 28898204 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg, qd)
Number of subjects: 308
Study 26135078 — intervention group
Group type: EXPERIMENTAL
Intervention: Handout directing to the ASSH web page on carpal tunnel syndrome in addition to standard care.
Number of subjects: 60
Study 26135078 — intervention group
Group type: COMPARATOR
Intervention: Standard care during a traditional physician office visit.
Number of subjects: 60
Study 26135078 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet usage (not specified if treatment or control).
Number of subjects: 60
Study 23636311 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 74
Study 21942317 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing and evaluating learning before selecting passages to restudy
Number of subjects: 0
Study 21942317 — intervention group
Group type: COMPARATOR
Intervention: Prompt questions without overt self-testing or evaluation
Number of subjects: 0
Study 21942317 — intervention group
Group type: COMPARATOR
Intervention: No prompts, simply given the menu for selecting passages to restudy
Number of subjects: 0
Study 21942317 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing with idea-unit judgments
Number of subjects: 0
Study 21942317 — intervention group
Group type: COMPARATOR
Intervention: Self-testing without idea-unit judgments
Number of subjects: 0
Study 19190927 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 23
Study 19190927 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 23
Study 17902062 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-magnesium-aspartate solution (Inzolen)
Number of subjects: 88
Study 17902062 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride
Number of subjects: 88
Study 15331332 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V plus antioxidant vitamins (beta carotene, alpha tocopherol and ascorbic acid)
Number of subjects: 516
Study 15331332 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin V
Number of subjects: 516
Study 11332784 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 15
Study 11332784 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 15
Study 9325826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing
Number of subjects: 44
Study 9325826 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 44
Study 7950508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg/day)
Number of subjects: 30
Study 7950508 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (7.5 mg/day)
Number of subjects: 30
Study 7950508 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 3604885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (160 to 800 mg/day, median 323 mg, mean 386 mg)
Number of subjects: 22
Study 3604885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 22
Study 2293801 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for children with asthma
Number of subjects: 253
Study 236804 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiamide 1 g daily by mouth
Number of subjects: 30
Study 236804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31078325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 243
Study 31078325 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoSequence root repair material (RRM)
Number of subjects: 243
Study 28898283 — intervention group
Group type: EXPERIMENTAL
Intervention: HAP plus EUC
Number of subjects: 495
Study 28898283 — intervention group
Group type: COMPARATOR
Intervention: EUC alone
Number of subjects: 495
Study 25020104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistacia atlantica Var. mutica mouthwash
Number of subjects: 28
Study 25020104 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 28
Study 25020104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23562525 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia (Zc)
Number of subjects: 6
Study 23562525 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined pure titanium (MPT)
Number of subjects: 6
Study 23562525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast and polished titanium (CPT)
Number of subjects: 6
Study 23562525 — intervention group
Group type: COMPARATOR
Intervention: Total cell count across all groups
Number of subjects: 6
Study 21272413 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation (15 mg/d)
Number of subjects: 387
Study 21272413 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation (30 mg/d)
Number of subjects: 387
Study 21272413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 18853107 — intervention group
Group type: COMPARATOR
Intervention: Venturi pump
Number of subjects: 49
Study 18853107 — intervention group
Group type: EXPERIMENTAL
Intervention: Peristaltic pump
Number of subjects: 49
Study 17074331 — intervention group
Group type: EXPERIMENTAL
Intervention: FHA
Number of subjects: 27
Study 17074331 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 14749754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-reduced, high-simple carbohydrate diet (SCHO)
Number of subjects: 46
Study 14749754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-reduced, high-complex carbohydrate diet (CCHO)
Number of subjects: 46
Study 14749754 — intervention group
Group type: COMPARATOR
Intervention: Normal-fat diet (control, CD)
Number of subjects: 46
Study 11384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives to improve follow-up for tuberculosis therapy after release from jail
Number of subjects: 254
Study 11384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Search strategies including phone calls, letters, and personal contacts
Number of subjects: 254
Study 11384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach efforts in shelters and drug/alcohol programs
Number of subjects: 254
Study 11384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach efforts in Latino community areas
Number of subjects: 254
Study 11384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary English speakers
Number of subjects: 254
Study 11384788 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects found back in jail
Number of subjects: 254
Study 9400508 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-based adjuvant chemotherapy
Number of subjects: 1568
Study 8121914 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P with low-dose hydroxy-urea (500 mg/day) maintenance therapy
Number of subjects: 237
Study 8121914 — intervention group
Group type: COMPARATOR
Intervention: 32P without hydroxy-urea maintenance therapy
Number of subjects: 237
Study 3303287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg three times daily for 2 weeks
Number of subjects: 20
Study 3303287 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 20
Study 3303287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20-40 mg three times daily during an open study in 30 patients
Number of subjects: 20
Study 30489620 — intervention group
Group type: COMPARATOR
Intervention: Volatile induction and maintenance anesthesia (VIMA) with sevoflurane and nitrous oxide
Number of subjects: 80
Study 30489620 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with remifentanil hydrochloride and propofol
Number of subjects: 80
Study 28478399 — intervention group
Group type: EXPERIMENTAL
Intervention: hUC-MSC (2×10^8 cells)
Number of subjects: 18
Study 28478399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28478399 — intervention group
Group type: EXPERIMENTAL
Intervention: hUC-MSC
Number of subjects: 18
Study 28478399 — intervention group
Group type: COMPARATOR
Intervention: hUC-MSC and Placebo
Number of subjects: 18
Study 26588261 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (8-10 a.m.)
Number of subjects: 10
Study 26588261 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (6-8 p.m.)
Number of subjects: 10
Study 23563576 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg b.i.d.
Number of subjects: 8436
Study 23563576 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg b.i.d.
Number of subjects: 8436
Study 21593649 — intervention group
Group type: EXPERIMENTAL
Intervention: Orafti Synergy1 (50 oligofructose:50 FOS) 0.4 g/dL
Number of subjects: 110
Study 21593649 — intervention group
Group type: EXPERIMENTAL
Intervention: Orafti Synergy1 (50 oligofructose:50 FOS) 0.8 g/dL
Number of subjects: 110
Study 21593649 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS:FOS (90:10) 0.8 g/dL
Number of subjects: 110
Study 21593649 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 110
Study 21593649 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 110
Study 17905788 — intervention group
Group type: EXPERIMENTAL
Intervention: Information Campaign (IC)
Number of subjects: 183
Study 17905788 — intervention group
Group type: COMPARATOR
Intervention: No Information Campaign (no-IC)
Number of subjects: 183
Study 16871715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal lacunarity analysis using a hyperbola model function to approximate the lacunarity function with coefficients alpha, beta, and gamma.
Number of subjects: 0
Study 12551829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (2,850 IU subcutaneously daily for 90 days)
Number of subjects: 59
Study 12551829 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (1 mg orally daily for 90 days)
Number of subjects: 59
Study 10589631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/mL
Number of subjects: 80
Study 10589631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/mL
Number of subjects: 80
Study 10589631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/mL
Number of subjects: 80
Study 10589631 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 80
Study 8724540 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-67 SPECT
Number of subjects: 33
Study 8724540 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 33
Study 8724540 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and 67Ga SPECT
Number of subjects: 33
Study 1912833 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for five years (539 patients)
Number of subjects: 1070
Study 1912833 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen for at least six weeks on confirmation of first recurrence (531 patients)
Number of subjects: 1070
Study 6638906 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg vaginally preoperatively and 500 mg intravenously during surgery)
Number of subjects: 112
Study 6638906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 27734127 — intervention group
Group type: EXPERIMENTAL
Intervention: WWCrB (Chromium-enriched yeast whole wheat bread)
Number of subjects: 30
Study 27734127 — intervention group
Group type: COMPARATOR
Intervention: WWB (Plain whole wheat bread)
Number of subjects: 30
Study 27894541 — intervention group
Group type: EXPERIMENTAL
Intervention: AcceleDent Aura appliance
Number of subjects: 40
Study 23765182 — intervention group
Group type: EXPERIMENTAL
Intervention: Advisor Teller Money Manager (ATM) money management intervention
Number of subjects: 90
Study 23765182 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 90
Study 22431675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 800 IU/d
Number of subjects: 163
Study 22431675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 600 IU/d (predicted)
Number of subjects: 163
Study 22431675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (various doses)
Number of subjects: 163
Study 22431675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 20977851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 73
Study 20977851 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 73
Study 18240113 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-focused Emotive Behavioural Therapy (SET)
Number of subjects: 93
Study 18240113 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 93
Study 16396443 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic susceptibility testing for Alzheimer's disease
Number of subjects: 60
Study 12610049 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day ramipril
Number of subjects: 4912
Study 12610049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4912
Study 9456256 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily filgrastim (1 microg/kg daily, adjusted up to 10 microg/kg daily)
Number of subjects: 258
Study 9456256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent filgrastim (300 microg daily one to three times per week to a maximum of 600 microg daily)
Number of subjects: 258
Study 9456256 — intervention group
Group type: COMPARATOR
Intervention: Control group (filgrastim if severe neutropenia developed)
Number of subjects: 258
Study 9456256 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim-treated patients
Number of subjects: 258
Study 8903614 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomized subjects
Number of subjects: 20
Study 8903614 — intervention group
Group type: COMPARATOR
Intervention: Healthy age‐matched normotensive controls
Number of subjects: 20
Study 2404346 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg at night)
Number of subjects: 58
Study 2404346 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (60 mg 3 times a day)
Number of subjects: 58
Study 713957 — intervention group
Group type: EXPERIMENTAL
Intervention: Biarison (900 mg to 1500 mg/day)
Number of subjects: 30
Study 713957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31067745 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 gummies (20,000 IU)
Number of subjects: 31
Study 31067745 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 tablets (20,000 IU)
Number of subjects: 31
Study 27068367 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (self-administered action observation treatment)
Number of subjects: 31
Study 27068367 — intervention group
Group type: COMPARATOR
Intervention: Control group (nature video)
Number of subjects: 31
Study 25449310 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at P6 point before chemotherapy infusion
Number of subjects: 70
Study 25449310 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg intravenously 30 min before chemotherapy infusion
Number of subjects: 70
Study 22952304 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced therapy
Number of subjects: 47
Study 22952304 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 47
Study 19190563 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL carbohydrate drink 2 hours before surgery
Number of subjects: 123
Study 19190563 — intervention group
Group type: COMPARATOR
Intervention: Nil per os after midnight (control group)
Number of subjects: 123
Study 19471137 — intervention group
Group type: COMPARATOR
Intervention: 40-minute exercise sessions (n = 198)
Number of subjects: 417
Study 19471137 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute exercise sessions (n = 219)
Number of subjects: 417
Study 19471137 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute myocardial infarction and/or coronary artery bypass graft surgery
Number of subjects: 417
Study 17237664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (100 to 400 mg/d or maximum tolerated dose)
Number of subjects: 119
Study 17237664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 17237664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 119
Study 15478383 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 19
Study 11466696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylotarg (gemtuzumab ozogamicin) therapy
Number of subjects: 119
Study 9466172 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg/day, range 300-600 mg/day)
Number of subjects: 624
Study 9466172 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day, range 10-30 mg/day)
Number of subjects: 624
Study 9466172 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 624
Study 9466172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 7737072 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus 2 months use of the tape player
Number of subjects: 41
Study 7737072 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 41
Study 7737072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (both groups)
Number of subjects: 41
Study 7737072 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the device
Number of subjects: 41
Study 7737072 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of devices
Number of subjects: 41
Study 2191018 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane sedation
Number of subjects: 60
Study 2191018 — intervention group
Group type: COMPARATOR
Intervention: Midazolam sedation
Number of subjects: 60
Study 226306 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol vaginal cream
Number of subjects: 29
Study 226306 — intervention group
Group type: COMPARATOR
Intervention: conjugated estrogen cream
Number of subjects: 29
Study 31471527 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent Retriever (SR)
Number of subjects: 336
Study 31471527 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 336
Study 31471527 — intervention group
Group type: COMPARATOR
Intervention: FPE patients (SR and CA combined)
Number of subjects: 336
Study 31471527 — intervention group
Group type: COMPARATOR
Intervention: Non-FPE patients
Number of subjects: 336
Study 31129279 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple arterial phase imaging (DISCO)
Number of subjects: 132
Study 31129279 — intervention group
Group type: COMPARATOR
Intervention: Single arterial phase imaging
Number of subjects: 132
Study 27495262 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system ON
Number of subjects: 28
Study 27495262 — intervention group
Group type: COMPARATOR
Intervention: Argus II retinal prosthesis system OFF
Number of subjects: 28
Study 24628553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro+CHO (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein with 60 g carbohydrate)
Number of subjects: 49
Study 24628553 — intervention group
Group type: COMPARATOR
Intervention: Pro (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein without carbohydrate)
Number of subjects: 49
Study 24628553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro+CHO
Number of subjects: 49
Study 24628553 — intervention group
Group type: COMPARATOR
Intervention: Pro
Number of subjects: 49
Study 22952178 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine intake of >500 mg · kg⁻¹ · d⁻¹
Number of subjects: 5